WCM
ABBV icon

Warburton Capital Management’s AbbVie ABBV Stock Holding History

Warburton Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-895
Closed -$204K – 69
2025
Q4 		$204K Sell
895
-243
-21% -$55.4K 0.12% 58
2025
Q3 		$278K Buy
1,138
+39
+4% +$7.94K 0.17% 44
2025
Q2 		$210K Buy
1,099
+69
+7% +$12.8K 0.12% 54
2025
Q1 		$215K Buy
+1,030
New +$200K 0.16% 43

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Warburton Capital Management's ABBV Position: Q1 2026 in Review

Warburton Capital Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 895 shares — an estimated $204K sold.

Warburton Capital Management first reported a position in ABBV in Q1 2025 and held it in 4 quarters. The position peaked at $278K in Q3 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Warburton Capital Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Warburton Capital Management sold 895 AbbVie shares in Q1 2026, an estimated $204K.
  • Warburton Capital Management first reported a position in AbbVie in Q1 2025 and held it in 4 quarters.
  • Warburton Capital Management's AbbVie position peaked at $278K in Q3 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Warburton Capital Management's 13F filing for Q1 2026, filed 1 May 2026.